STERIS' (STE) revenues at AST improve driven by increased demand from medical device and biopharma customers.
Steris (STE) delivered earnings and revenue surprises of 0% and 5.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
First quarter revenue increases 19% as reported; 6% constant currency organicAs reported EPS of $1.10; adjusted EPS of $1.90Updated outlook provided ...
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q1 sales.
McKesson's (MCK) fiscal first-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
QuidelOrtho's (QDEL) second-quarter results are likely to reflect strength across both its COVID and non-COVID businesses.
DUBLIN, IRELAND, July 28, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a...
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integr's (IART) year-over-year growth in both the CSS and Tissue Technology segments buoys optimism.
The dull underlying market situation, impacted by macro-economic environmental factors and lingering effects of COVID-19 variants in certain markets, impacts Align Technology's (ALGN) Q2 results.